- Home
- Publications
- Publication Search
- Publication Details
Title
The Changing Therapeutic Landscape of Metastatic Renal Cancer
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 9, Pages 1227
Publisher
MDPI AG
Online
2019-08-23
DOI
10.3390/cancers11091227
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of biomarkers in the prediction of response to therapeutics in metastatic renal cell carcinoma
- (2019) Jacob J. Adashek et al. Clinical Genitourinary Cancer
- A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
- (2019) Caroline E. Nunes-Xavier et al. Current Urology Reports
- Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy
- (2019) Alessia Cimadamore et al. Cancers
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overview of current and future systemic therapy for metastatic renal cell carcinoma
- (2019) Takahiro Osawa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
- (2019) Matthew K. Labriola et al. Clinical Genitourinary Cancer
- Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions
- (2019) Carina Schey et al. ADVANCES IN THERAPY
- Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial
- (2019) Sergio Bracarda et al. Clinical Genitourinary Cancer
- Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2019) I. Stukalin et al. Current Oncology
- The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions
- (2019) Nicholas J. Salgia et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Efficacy and safety of perioperative appliance of sunitinib in patients with metastatic or advanced renal cell carcinoma
- (2019) Hongyu Jin et al. MEDICINE
- Towards individualized therapy for metastatic renal cell carcinoma
- (2019) Ritesh R. Kotecha et al. Nature Reviews Clinical Oncology
- Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
- (2019) Andreas Kahlmeyer et al. Journal of Clinical Medicine
- Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
- (2019) Daniele Lecis et al. Cancers
- Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma
- (2019) Fady Ghali et al. Journal of Oncology
- The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma
- (2019) ALEXANDER J. CHANG et al. ANTICANCER RESEARCH
- Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
- (2019) A.Y. Shah et al. EUROPEAN JOURNAL OF CANCER
- PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
- (2019) Joseph Vento et al. Journal for ImmunoTherapy of Cancer
- Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma
- (2019) Chen et al. Cancers
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- (2019) Laurence Albiges et al. EUROPEAN UROLOGY
- Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma
- (2018) José I. López et al. Annals of Diagnostic Pathology
- Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals
- (2018) Zhun Wang et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- (2018) Thomas Powles et al. EUROPEAN UROLOGY
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
- (2018) David Cella et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- (2018) Arnaud Méjean et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
- (2018) José I. López et al. PATHOLOGY RESEARCH AND PRACTICE
- Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
- (2018) Jason Zhu et al. Journal for ImmunoTherapy of Cancer
- Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
- (2018) Hayriye Tatli Dogan et al. Diagnostic Pathology
- Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
- (2018) Axel Bex et al. EUROPEAN UROLOGY
- Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
- (2018) Xin Gao et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
- (2018) Melissa Bersanelli et al. Cancer Management and Research
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
- (2018) Axel Bex et al. JAMA Oncology
- The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling
- (2018) Estíbaliz López-Fernández et al. Cancers
- Multisite tumor sampling: a new tumor selection method to enhance intratumor heterogeneity detection
- (2017) José I. López et al. HUMAN PATHOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton
- (2017) Henrick Horita et al. NEOPLASIA
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status
- (2016) Yosra Messai et al. EUROPEAN UROLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
- (2016) Ricardo Costa et al. Oncotarget
- Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status
- (2015) Su-Jin Shin et al. ANNALS OF SURGICAL ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. Targeted Oncology
- First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
- (2014) J J Ko et al. BRITISH JOURNAL OF CANCER
- The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
- (2014) A. Ribas et al. CLINICAL CANCER RESEARCH
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Sorafenib for the treatment of renal cancer
- (2012) Dirk Strumberg EXPERT OPINION ON PHARMACOTHERAPY
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started